CL2004000643A1 - Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. - Google Patents

Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.

Info

Publication number
CL2004000643A1
CL2004000643A1 CL200400643A CL2004000643A CL2004000643A1 CL 2004000643 A1 CL2004000643 A1 CL 2004000643A1 CL 200400643 A CL200400643 A CL 200400643A CL 2004000643 A CL2004000643 A CL 2004000643A CL 2004000643 A1 CL2004000643 A1 CL 2004000643A1
Authority
CL
Chile
Prior art keywords
treatment
agonist
selective
cyclloxygenasa
migrane
Prior art date
Application number
CL200400643A
Other languages
English (en)
Inventor
Seibert Karen
Original Assignee
Pharmacia Corp Sa Organizada B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33310695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp Sa Organizada B filed Critical Pharmacia Corp Sa Organizada B
Publication of CL2004000643A1 publication Critical patent/CL2004000643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

COMPOSICION QUE COMPRENDE A UN AGONISTA DED 5-HT1B/D O UN ISOMERO, SAL FARMACEUTICAMENTE ACEPTABLE, ESTER O PRODROGA DELE MISMO Y UN INHBIDOR SELECTIVO DE CICLOOXIGANASA-2 Y SU USO PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO Y LA PREVENCION DE LA MIGRANA.
CL200400643A 2003-03-28 2004-03-26 Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. CL2004000643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45886803P 2003-03-28 2003-03-28

Publications (1)

Publication Number Publication Date
CL2004000643A1 true CL2004000643A1 (es) 2005-03-18

Family

ID=33310695

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400643A CL2004000643A1 (es) 2003-03-28 2004-03-26 Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.

Country Status (9)

Country Link
US (1) US20040214861A1 (es)
EP (1) EP1608361A4 (es)
JP (1) JP2006521353A (es)
BR (1) BRPI0408902A (es)
CA (1) CA2520527A1 (es)
CL (1) CL2004000643A1 (es)
MX (1) MXPA05010476A (es)
TW (1) TW200509924A (es)
WO (1) WO2004093826A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115586A1 (en) * 2007-03-21 2008-09-25 Alza Corporation Apparatus and method for transdermal delivery of a triptan agonist
CA2815437A1 (en) * 2009-10-23 2011-04-28 Fortuderm, Ltd. Triptans for the treatment of psoriasis
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN110621314A (zh) * 2017-01-04 2019-12-27 艾克萨姆治疗公司 包含美洛昔康的药物组合物
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) * 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN117017997A (zh) * 2017-05-10 2023-11-10 艾克萨姆治疗公司 包含美洛昔康的药物组合物
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20210027371A (ko) * 2018-07-03 2021-03-10 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
EP3920909A4 (en) * 2019-02-06 2022-11-30 Axsome Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DE69739003D1 (de) * 1996-04-12 2008-10-30 Searle Llc Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9929040D0 (en) * 1999-12-08 2000-02-02 Glaxo Group Ltd Medicaments
US20020009421A1 (en) * 2000-06-01 2002-01-24 Wilder Karol J. Therapy following skin injury from exposure to ultraviolet radiation
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain

Also Published As

Publication number Publication date
US20040214861A1 (en) 2004-10-28
EP1608361A2 (en) 2005-12-28
TW200509924A (en) 2005-03-16
MXPA05010476A (es) 2005-11-16
CA2520527A1 (en) 2004-11-04
EP1608361A4 (en) 2006-08-16
BRPI0408902A (pt) 2006-03-28
JP2006521353A (ja) 2006-09-21
WO2004093826A3 (en) 2005-10-27
WO2004093826A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CL2004000643A1 (es) Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
NO20072839L (no) 4-hydroksybenzomorfaner
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
RS52777B (en) CURRENT RELEASE THERAPY SYSTEM FOR IMPROVED ORAL ABSORPTION 7 - [(E) -TERT-BUTYLOXYIMINOMETHYL] CAMPTOTECIN
ATE308522T1 (de) Opioidrezeptorantagonisten
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
SE0302488D0 (sv) New combination
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
ATE306924T1 (de) 2-substituierte 1-arylpiperazine als tachykinin- antagonisten und/oder serotonin-wiederaufnahme- hemmer
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
NO20052491D0 (no) Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme
AR041595A1 (es) Tratamiento terapeutico
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения